Minimal Residual Disease Monitoring In t(8;21) Acute ...
Recommend Documents
Leroy H, de Botton S, Grardel-. Duflos N, Darre S, Leleu X, Roumier. C, et al. ... Sievers EL, Lange BJ, Alonzo TA,. Gerbing RB, Bernstein ID, Smith FO, et al.
between MRD and event-free survival by looking at relapse, the primary determinant of event- free survival and the biolo
12 Komp DM, Fisher DB, Sabio H, McIntosh S. Frequency of bone marrow aspirates to ... 25 Blennerhassett GT, Furth ME, Anderson A, Burns JP,. Chaganti RS, Blick M, et al. ..... Blood 1991;77:1989-95. 89 Owen RG, Child JA, Rawson A, et al.
Oct 20, 2016 - Maria Ilaria Del Principe1, Francesco Buccisano1, Luca Maurillo1, ...... Testoni N, Abbenante MC, Paolini S, Sartor C, Parisi S, Marconi.
The prognostic relevance of minimal residual disease (MRD) in patients with multiple ... to evaluate whether these circulating tumor cells play a role in promoting disease recurrence. ... rare, and patient numbers of reported results are very low.
Apr 18, 2012 - This report describes the clinical courses of two acute myeloid leukemia patients. ... Keywords: Minimal residual disease, Haploidentical stem cell transplantation, MLL, KIR, ... Experimental Hematology & Oncology 2012, 1:6.
Oct 1, 2012 - Gene rearrangement study for minimal residual disease monitoring in children ..... Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA.
Defined as the lack of MRD at a specific time point with polymerase chain .... minimal residual disease; NGF next-genera
Feb 6, 2013 - Methods: We investigated whether MRD status in adult patients with ALL is useful to ... 1Division of Hematology and Oncology, Department of Medicine, Kurume ..... ALL has been reported to be useful for identifying patients.
Minimal Residual Disease Monitoring In t(8;21) Acute ...
Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-‐RUNX1T1 Fusion QuanBficaBon On Genomic DNA Nicolas Duployez, Aline Renneville, Olivier Nibourel, Alice Marceau-‐Renaut, Nathalie Helevaut, Aurélie Caillault, Celine Villenet, Karine Celli-‐Lebras, Nicolas Boissel, Eric Jourdan, Herve Dombret, MarFn Figeac and Claude Preudhomme
Background Although acute myeloid leukemia (AML) with t(8;21) belongs to the favorable risk AML subset, relapse incidence may reach 30-‐40% in those paFents. Minimal residual disease monitoring (MRD) based on the quanFficaFon of RUNX1-‐ RUNX1T1 fusion transcript by real-‐Fme quanFtaFve PCR (RQ-‐PCR) has been o bbe e an independent prognosFc factor for the risk of relapse. reported tto an independent prognosFc factor for the risk of relapse. In this study, we invesFgated the feasibility and performances of RUNX1-‐ RUNX1T1 DNA as MRD marker in AML with t(8;21).
